BRIEF published on 11/05/2024 at 10:12, 1 year ago Leadership Transition at PharmaSGP Holding SE: Peter Gerckens to Succeed Natalie Weigand as CEO Company Growth OTC Pharmaceuticals Peter Gerckens Natalie Weigand PharmaSGP Leadership Change
PRESS RELEASE published on 11/05/2024 at 10:07, 1 year ago CEO change at PharmaSGP Holding SE: Peter Gerckens succeeds Natalie Weigand as of January 1, 2025 PharmaSGP Holding SE announces CEO change with Peter Gerckens succeeding Natalie Weigand on January 1, 2025. Smooth transition planned for internal succession Succession Plan CEO Change PharmaSGP Holding SE Peter Gerckens Natalie Weigand
BRIEF published on 11/05/2024 at 10:07, 1 year ago Leadership Change at PharmaSGP Holding SE: Peter Gerckens Appointed CEO Leadership Transition CEO Change PharmaSGP Holding SE Peter Gerckens Natalie Weigand
PRESS RELEASE published on 11/05/2024 at 10:02, 1 year ago EQS-Adhoc: PharmaSGP Holding SE: Peter Gerckens succeeds Natalie Weigand as Chief Executive Officer PharmaSGP Holding SE appoints Peter Gerckens as new CEO, succeeding Natalie Weigand. Gerckens, currently CCO, will assume the CEO position on January 1, 2025 Supervisory Board PharmaSGP Holding SE CEO Succession Peter Gerckens Natalie Weigand
BRIEF published on 10/01/2024 at 08:20, 1 year 2 months ago PharmaSGP Holding SE Acquires 477,701 Shares Through Repurchase Offer Share Buyback Treasury Shares Capital Reduction PharmaSGP Repurchase Offer
PRESS RELEASE published on 10/01/2024 at 08:15, 1 year 2 months ago PharmaSGP Holding SE has purchased 477,701 own shares through its public share repurchase offer PharmaSGP Holding SE has purchased 477,701 own shares through public share repurchase offer. The company's acceptance ratio is approximately 80.37% Share Buyback Treasury Shares Public Offer PharmaSGP Holding Acceptance Ratio
BRIEF published on 09/12/2024 at 08:20, 1 year 2 months ago PharmaSGP Continues Dynamic Growth Path in First Half of 2024 Revenue Growth International Expansion PharmaSGP OTC Pharmaceuticals 2024 Financials
BRIEF published on 09/12/2024 at 08:15, 1 year 2 months ago PharmaSGP Holding SE Announces Share Repurchase Program Share Repurchase Acceptance Period PharmaSGP Holding SE 594,405 Shares EUR 21.45
PRESS RELEASE published on 09/12/2024 at 08:15, 1 year 2 months ago PharmaSGP continues dynamic growth path in the first half of 2024 PharmaSGP Holding SE reports dynamic growth with half-year revenues reaching €58.4 million, up 17.4% from last year. Management expects full-year revenues to range from €107.0m to €112.0m Revenues Germany Growth Internationalization PharmaSGP
PRESS RELEASE published on 09/12/2024 at 08:10, 1 year 2 months ago EQS-Adhoc: PharmaSGP Holding SE resolves on public share repurchase offer to buy back own shares for up to 594,405 shares PharmaSGP Holding SE announces public share repurchase offer to buy back own shares for up to 594,405 shares, with acceptance period from September 13 to 26, 2024 Acceptance Period 2024 PharmaSGP Holding SE 594,405 Shares Share Repurchase Offer
Published on 12/05/2025 at 02:35, 4 hours 42 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 6 hours 17 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 8 hours 12 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 8 hours 17 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 07:00, 16 minutes ago Swiss Re targets a net income of USD 4.5 billion in 2026; refreshed strategy to strengthen core business
Published on 12/05/2025 at 03:30, 3 hours 46 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 7 hours 26 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 51 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 11 hours 2 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 18:00, 13 hours 17 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 13 hours 32 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 13 hours 33 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 13 hours ago Declaration of voting rights at the end of November 2025
